Short- and long-term modulation of microvascular responses in streptozotocin-induced diabetic rats by glycosylated products

Journal of Diabetes and its Complications

Volumn 24, Issue 1, 2010, Pages 64-72

  Bassirat, Maryam ^a   Khalil, Zeinab ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF SHARJAH   (United Arab Emirates)

Author keywords

AGEs; Amadori; Aminoguanidine; Neurogenic inflammation; Streptozotocin

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ADVANCED GLYCATION END PRODUCT RECEPTOR ANTIBODY; AMADORI; AMINOGUANIDINE; IMMUNOGLOBULIN G; INSULIN; NITROPRUSSIDE SODIUM; SUBSTANCE P; UNCLASSIFIED DRUG; VASOACTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLISTER; BLOOD FLOW; CONTROLLED STUDY; DRUG SYNTHESIS; EXTRAVASATION; GLUCOSE BLOOD LEVEL; INFLAMMATION; INSULIN TREATMENT; MALE; MICROVASCULATURE; MODULATION; NONHUMAN; PRIORITY JOURNAL; RAT; STREPTOZOCIN DIABETES; VACUUM; VASODILATATION; WEIGHT GAIN;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DISEASE MODELS, ANIMAL; EXUDATES AND TRANSUDATES; FOOT; GLYCOSYLATION; GLYCOSYLATION END PRODUCTS, ADVANCED; GUANIDINES; INFLAMMATION; MALE; MICROVESSELS; PEPTIDES; PERFUSION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, IMMUNOLOGIC; REGIONAL BLOOD FLOW; TIME FACTORS; VASODILATION;

EID: 70749087660     PISSN: 10568727     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2008.10.001     Document Type: Article

References (42)

1. Ahmed M.S., and Ahmed N. Antiglycation properties of aged garlic extract: Possible role in prevention of diabetic complications. Journal of Nutrition 136 (2006) 796S-799S
2. Ahmed N., and Furth A.J. A microassay for protein glycation based on the periodate method. Annals of Biochemistry 192 (1991) 109-111
3. 2 opens BKca channels via the PLA2-arachidonic acid signalling cascade in coronary artery smooth muscle. American Journal of Physiology Heart and Circulatory Physiology 279 (2000) H475-H483
4. Bassirat M., and Khalil Z. The role of endothelin and superoxide anions in modulating inflammation in streptozotocin-induced diabetic rat model. Microvascular Research 59 (2000) 88-98
5. Brain S.D., and Williams T.J. Substance P regulates the vasodilator activity of calcitonin gene-related peptide. Nature 335 (1988) 73-75
6. Brem H., and Tomic-Canic M. Cellular and molecular basis of wound healing in diabetes. Journal of Clinical Investigation 117 (2007) 1219-1222
7. Bonnardel-Phu E., Wautier J., and Vicaut E. Advanced glycation end-products are involved in permeability changes observed in microcirculation of diabetic rats in vivo. Journal Des Maladies Vasculaires 25 (2000) 122-127
8. Cameron N.E., Gibson T.M., Nangle M.R., and Cotter M.A. Inhibitors of advanced glycation end product formation and neurovascular dysfunction in experimental diabetes. Annals of the New York Academy of Sciences 1043 (2005) 784-792
9. Chang K.C., Hsu K.L., Tseng C.D., Lin Y.D., Cho Y.L., and Tseng Y.Z. Aminoguanidine prevents arterial stiffening and cardiac hypertrophy in streptozotocin-induced diabetes in rats. British Journal of Pharmacology 147 (2006) 944-950
10. Corbett J.A., and McDaniel M.L. The use of aminoguanidine, a selective iNOS inhibitor, to evaluate the role of nitric oxide in the development of autoimmune diabetes. Methods 10 (1996) 21-30
11. Crijns F.R.L., Struijker Boudier H.A.J., and Wofflenbuttel B.H.R. Arteriolar reactivity in conscious diabetic rats: Influence of aminoguanidine treatment. Diabetes 47 (1998) 918-923
12. Elgawish A., Glomb M., Friedlander M., and Monnier V. Involvement of hydrogen peroxide in collagen cross-linking by high glucose in vitro and in vivo. Journal of Biological Chemistry 271 (1996) 12964-12971
13. Forbes J.M., Fukami K., and Cooper M.E. Diabetic neuropathy: Where hemodynamics meets metabolism. Experimental and Clinical Endocrinology and Diabetes 115 (2007) 69-84
14. Giardino I., Fard A.K., Hatchell D.L., and Brownlee M. Aminoguanidine inhibits reactive oxygen species formation, lipid peroxidation, and oxidant-induced apoptosis. Diabetes 47 (1998) 1114-1120
15. Guo X.H., Huang Q.B., Chen B., Wang S.Y., Hou F.F., and Fu N. Mechanism of advanced glycation end products-induced hyperpermeability in endothelial cells. Sheng Li Xue Bao 57 (2005) 205-210
16. Hill M., and Larkins R.G. Alterations in distribution of cardiac output in experimental diabetes in rats. American Journal of Physiology 257 (1989) H571-H580
17. Jerums G., Panagiotopolous S., Forbes J., Osicka T., and Cooper M. Evolving concepts in advanced glycation, diabetic nephropathy, and diabetic vascular disease. Archives of Biochemistry and Biophysics 419 (2003) 55-62
18. Khalil Z., and Helme R.D. Sequence of events in substance P-mediated plasma extravasation in rat skin. Brain Research 500 (1989) 256-262
19. Lalla E., Lamster I.B., Stern D.M., and Schmidt A.M. Receptor for advanced glycation end products, inflammation, and accelerated periodontal disease ion diabetes: Mechanisms and insights into therapeutic modalities. Annals of Periodontology 6 (2001) 113-118
20. Li Y.M., Steffes M., Donnelly T., Liu T., Fuh H., Basgen J., et al. Prevention of cardiovascular and renal pathology of aging by the advanced glycation inhibitor aminoguanidine. Proceedings of the National Academy of Sciences of the United States of America 93 (1996) 3902-3907
21. Mene P., Pascale C., Teti A., Bernardini S., Cinotti G.A., and Pugliese F. Effects of advanced glycation end-products on cytosolic calcium signalling of cultured human mesangial cells. Journal of the American Society of Nephrology 10 (1999) 1478-1486
22. Mossine V.V., Linetsky M., Glinsky G.V., Ortwerth B.J., and Feather M.S. Superoxide free radical generation by Amadori compounds: the role of acyclic forms and metal ions. Chemical Research in Toxicology 12 (1999) 230-236
23. Nawale R.B., Mourya V.K., and Bhise S.B. Non-enzymatic glycation of proteins: A cause for complications in diabetes. Indian Journal of Biochemistry and Biophysics 43 (2006) 337-344
24. Nyengaard J.R., Chang K., Berhorst S., Reiser K.M., and Williamson J.R. Discordant effects of guanidines on renal structure and function and on regional vascular dysfunction and collagen changes in diabetic rats. Diabetes 46 (1997) 94-106
25. Ou P., and Wolff S.P. Aminoguanidine: a drug proposed for the prophylaxis in diabetes inhibits catalase and generates hydrogen peroxide in vitro. Biochemical Pharmacology 46 (1993) 1139-1144
26. Quehenberger P., Bierhaus A., Faschaing P., Muellner C., Klevesath M., Hong M., et al. Endothelin-1 transcription is controlled by nuclear factor-KappaB in AGE-stimulated cultured endothelial cells. Diabetes 49 (2000) 1561-1570
27. Ramasamy R., Vannucci S.J., Yan S.S.D., Kevan H., Yan S.F., and Schmidt A.M. Advanced glycation end-products and RAGE: A common threat in aging, diabetes, neurodegeneration, and inflammation. Glycobiology 15 (2005) 16R-28R
28. Rumble J.R., Cooper M.E., Soulis-Liporata T., Cox A., Wu L., Youssef S., et al. Vascular hypertrophy in experimental diabetes: Role of advanced glycation end-products. Journal of Clinical Investigation 99 (1997) 1016-1027
29. Ryle C., Leow C.K., and Donaghy M. Nonenzymatic glycation of peripheral and central nervous system proteins in experimental diabetes mellitus. Muscle and Nerve 20 (1997) 577-584
30. Sakata N., Miyamoto K., Meng J., Tachikawa Y., Imanaga Y., Takebayashi S., et al. Oxidative damage of vascular smooth muscle cells by the glycated protein-cupric ion system. Atherosclerosis 136 (1998) 263-274
31. Schmidt A.M., Crandall J., Hori O., Cao R., and Lakatta E. Elevated plasma levels of vascular cell adhesion molecule-1 (VCAM-1) in diabetic patients with microalbuminuria: A marker of vascular dysfunction and progressive vascular disease. British Journal of Haematology 92 (1996) 747-750
32. Shin A.H., Oh C.J., and Park J.W. Glycation-induced inactivation of antioxidant enzymes and modulation of cellular redox status in lens cells. Archives of Pharmacological Research 29 (2006) 577-581
33. Skamarauskas J.T., McKay A.G., and Hunt J.V. Aminoguanidine and its pro-oxidant effects on an experimental model of protein glycation. Free Radical, Biology and Medicine 21 (1996) 801-812
34. Soulis-Liparota T., Cooper M., Vranes D., Bucala R., and Jerums G. Effects of aminoguanidine in preventing experimental diabetic nephropathy are related to the duration of treatment. Kidney International 50 (1996) 627-634
35. Stitt A.W. The Maillard reaction in eye diseases. Annals of the New York Academy of Science 1043 (2005) 582-597
36. Ulusu N.N., Sahilli M., Avci A., Canbolat O., Ozansoy G., Ari N., et al. Pentose phosphate pathway, glutathione-dependent enzymes and antioxidant defence during oxidative stress in diabetic rodent brain and peripheral organs: effects of stobadine and vitamin E. Neurochemical Research 28 (2003) 815-823
37. Vallejo S., Angulu J., Peiro C., Nevado J., Sanchez-Ferrer A., Petidier R., et al. Highly glycated oxyhaemoglobin impairs nitric oxide relaxations in human mesenteric microvessels. Diabetologia 43 (2000) 83-90
38. Vlassara H., Fuh H., Makita Z., Krungkrai S., Cerami A., and Bucala R. Exogenous advanced glycosylation end-products induce complex vascular dysfunction in normal animals: a model for diabetic and aging complications. Proceedings of the National Academy of Sciences of the United States of America 89 (1992) 12043-12047
39. Wautier J.L., and Guillausseau P.J. Diabetes, advanced glycation end-products and vascular disease. Vascular Medicine 3 (1998) 131-137
40. Wautier J.L., and Schmidt A.M. Protein glycation: A firm link to endothelial cell dysfunction. Circulation Research 95 (2004) 233-252
41. Wautier J.L., Zoukourian C., Chappey O., Wautier M.P., Guillausseau P.J., Cao R., et al. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end-products blocks hyperpermeability in diabetic rats. Journal of Clinical Investigation 97 (1996) 238-243
42. Yu Y., Thorpe S.R., Jenkins A.J., Shaw J.N., Sochaski M.A., McGee D., et al. Advanced glycation end-products and methionine sulphoxide in skin collagen of patients with type 1 diabetes. Diabetologia 49 (2006) 2488-2498